MONOPAR THERAPEUTICS (MNPR): Price and Financial Metrics
GET POWR RATINGS... FREE!
MNPR Stock Price Chart Interactive Chart >
MNPR Price/Volume Stats
| Current price | $3.50 | 52-week high | $4.88 |
| Prev. close | $3.36 | 52-week low | $1.39 |
| Day low | $3.15 | Volume | 123,400 |
| Day high | $3.54 | Avg. volume | 26,128 |
| 50-day MA | $2.63 | Dividend yield | N/A |
| 200-day MA | $2.24 | Market Cap | 45.22M |
MONOPAR THERAPEUTICS (MNPR) Company Bio
Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
Latest MNPR News From Around the Web
Below are the latest news stories about MONOPAR THERAPEUTICS that investors may wish to consider to help them evaluate MNPR as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuedayWe're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! |
Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore CollaborationWILMETTE, Ill, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today released promising data with MNPR-202 from its ongoing collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS). The data are displayed in the poster that NUS and Monopar |
Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study DataMonopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tissue sarcoma. |
Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowMonopar Therapeutics Inc. (MNPR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
MNPR Price Returns
| 1-mo | 46.44% |
| 3-mo | 70.73% |
| 6-mo | 72.30% |
| 1-year | 21.62% |
| 3-year | -82.05% |
| 5-year | N/A |
| YTD | 47.68% |
| 2022 | -26.17% |
| 2021 | -47.55% |
| 2020 | -63.13% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...